Multimodal Imaging Techniques and Theragnostic Approaches for Diagnosis and Treatment of Cancer
Abstract
Since cancer is a complex illness, a multimodal strategy with a multidisciplinary team is necessary. Currently, chemotherapy, surgery, and/or radiation therapy are used in combination to treat cancer. Chemotherapy is currently recognized as the most effective cancer treatment, despite the fact that it is known to induce severe side effects in patients due to its non-discriminatory adverse effect on both normal and malignant cells. Understanding how drugs are distributed throughout organs and creating a site-specific drug delivery strategy that targets cancer cells are the primary problems in cancer and other complex chemotherapeutic diseases. Thus, it is essential to create innovative methods for the traceable and targeted delivery of anti-cancer drugs. This review article's objective is to provide an overview of current tumor therapy methods and discuss their potential benefits in a multimodal strategy. There is growing optimism that significant improvements in illness diagnosis and treatment may result from the use of nanotechnology in medicine. Additionally, this review article offers an overview of multifunctional nanostructures used in medication delivery and cancer therapy.
Keywords:
Multimodal approach , Theragnostic, Multimodality imaging, Multimodal care, Modern imagingDOI
https://doi.org/10.25004/IJPSDR.2025.170309References
Morani DO, Patil PO. Review on Multifunctional Nanotherapeutics for Drug Delivery, Tumor Imaging, and Selective Tumor Targeting by Hyaluronic Acid Coupled Graphene Quantum Dots. Current Nanoscience. 2024;20:89-108. Available from: doi.org/10.2174/1573413719666230210122445
Morani DO, Patil PO, Jain AS. Recapitulation of Cancer Nanotherapeutic. Current Nanomedicine. 2021;11:3-15. Available from: doi.org/10.2174/2468187311666210121143501
Morani, DO, Patil, PO. Formulation and evaluation of hyaluronic acid and adipic acid dihydrazide modified graphene quantum dot-based nanotherapeutics for paclitaxel-targeted delivery in breast cancer. Future J Pharm Sci. 2025;11. Available from: doi.org/10.1186/s43094-024-00754-7
Patil SV, Bavaskar RK, Morani DO, Jain AS. Review on Hyaluronic Acid Functionalized Sulfur and Nitrogen Co-Doped Graphene Quantum Dots Nano Conjugates for Targeting of Specific Type of Cancer. Adv Pharm Bull. 2024 Jul;14(2):266-277. Available from: doi.org/10.34172/apb.2024.043
Morani DO & Patil PO. Preparation, Characterization, and Cytotoxicity Study of Nitrogen-Doped Graphene Quantum Dots Functionalized Hyaluronic Acid Loaded with Docetaxel-Catalyzed Nanoparticles for Breast Cancer Imaging and Targeting In Vitro. Journal of Macromolecular Science, Part B. 2024;1:1-25. Available from: doi.org/10.1080/00222348.2024.2429915
Pene F, Courtine E, Cariou A, Mira JP. Toward theragnostics. Crit. Care Med. 2009;37:S50-S58. Available from: doi.org/10.1097/ccm.0b013e3181921349
Ozdemir V, Williams-Jones B, Glatt SJ, Tsuang MT, Lohr JB, Reist C. Shifting emphasis from pharmacogenomics to theragnostics. Nat. Biotechnol. 2006;24:942-947. Available from: doi.org/10.1038/nbt0806-942
Shubayev VI, Pisanic TR, Jin SH. Magnetic nanoparticles for theragnostics. Adv. Drug Deliv. Rev. 2009;61:467-477. Available from: doi.org/10.1016/j.addr.2009.03.007
Del Vecchio, S.; Zannetti, A.; Fonti, R.; Pace, L.; Salvatore, M. Nuclear imaging in cancer theranostics. Q. J. Nucl. Med. Mol. Imaging, 2007, 51, 152-163.
Lucignani, G. Nanoparticles for concurrent multimodality imaging and therapy: the dawn of new theragnostic synergies. Eur. J. Nucl. Med. Mol. Imaging. 2009;36:869-874. Available from: doi.org/10.1007/s00259-009-1104-2
Burga RA, Patel S, Bollard CM, Y Cruz CR, Fernandes R. Conjugating prussian blue nanoparticles onto antigen-specific T cells as a combined nanoimmunotherapy. Nanomedicine. 2016;11:1759–1767. Available from: doi.org/10.2217/nnm-2016-0160
Cappello P and Novelli F. Next generation of cancer immunotherapy calls for combination. Oncoscience. 2017;31:19-20. Available from: doi.org/10.18632/oncoscience.343
Torres MR, Tavare R, Glaria A, Varma G, Protti A, Blower PJ. Tc-bisphosphonate-iron oxide nanoparticle conjugates for dual-modality biomedical imaging. Bioconjugate Chem. 2011;22:455–465. Available from: doi.org/10.1021/bc100483k
Jennings LE, Long, NJ. ‘Two is better than one’—Probes for dual-modality molecular imaging. Chem. Commun. (Camb.). 2009:3511–3524. Available from: doi.org/10.1039/b821903f
Heidt T, Nahrendorf M. Multimodal iron oxide nanoparticles for hybrid biomedical imaging. NMR Biomed. 2012;26:756–765. Available from: doi.org/10.1002/nbm.2872
Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat. Rev. Drug Discov. 2008;7:591–607. Available from: doi.org/10.1038/nrd2290
Kirui DK, Khalidov I, Wang Y, Batt CA. Targeted near-ir hybrid magnetic nanoparticles for in vivo cancer therapy and imaging. Nanomed. Nanotechnol. Biol. Med. 2012;9:702–711. Available from: doi.org/10.1016/j.nano.2012.11.009
Misri R, Meier D, Yung AC, Kozlowski P, Hafeli UO. Development and evaluation of a dual-modality (mri/spect) molecular imaging bioprobe. Nanomed. Nanotechnol. Biol. Med. 2012;8:1007–1016. Available from: doi.org/10.1016/j.nano.2011.10.013
O’Farrell A, Shnyder S, Marston G, Coletta P, Gill J. Non-invasive molecular imaging for preclinical cancer therapeutic development. Br. J. Pharmacol. 2013;169:719–735. Available from: doi.org/10.1111/bph.12155
Hendee MC. Magnetic resonance imaging. Part1-physical principles. West J. Med. 1984;141:491–500.
Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat. Rev. Cancer. 2002;2:683-693. Available from: doi.org/10.1038/nrc882
Cassidy PJ, Radda GK. Molecular imaging perspectives. J. R. Soc. Interface R. Soc. 2005;2:133–144. Available from: doi.org/10.1098/rsif.2005.0040
Wang, H. Agents that induce pseudo-allergic reaction. Drug Discov. Ther. 2011;5:211–219. Available from: doi.org/10.5582/ddt.2011.v5.5.211
Goldman LW. Principles of ct and ct technology. J. Nuclear Med. Technol. 2007;35: 115–128. Available from: doi.org/10.2967/jnmt.107.042978
Hasebroock KM, Serkova NJ. Toxicity of mri and ct contrast agents. Expert Opin. Drug Metabol. Toxicol. 2009;5:403–416. Available from: doi.org/10.1517/17425250902873796
Giljohann DA, Seferos DS, Daniel WL, Massich MD, Patel PC, Mirkin CA. Gold nanoparticles for biology and medicine. Angew. Chem. Int. Ed. Engl. 2010;49:3280–3294. Available from: doi.org/10.1002/anie.200904359
Ntziachristos V, Bremer C, Weissleder R. Fluorescence imaging with near-infrared light: New technological advances that enable in vivo molecular imaging. Eur. Radiol. 2003;13:195–208. Available from: doi.org/10.1007/s00330-002-1524-x
Pierce MC, Javier DJ, Richards-Kortum R. Optical contrast agents and imaging systems for detection and diagnosis of cancer. Int. J. Cancer. 2008;123:1979–1990. Available from: doi.org/10.1002/ijc.23858
Shah K, Weissleder R. Molecular optical imaging: Applications leading to the development of present-day therapeutics. Neurotherapeutics. 2005;2:215–225. Available from: doi.org/10.1602/neurorx.2.2.215
Cai W, Chen X. Nanoplatforms for targeted molecular imaging in living subjects. Small. 2007;3:1840–1854. Available from: doi.org/10.1002/smll.200700351
Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003;17:545-580. Available from: doi.org/10.1101/gad.1047403
Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik DE, Aikawa E, et al. Nanoparticle pet-ct imaging of macrophages in inflammatory atherosclerosis. Circulation. 2008;117:379–387. Available from: doi.org/10.1161/CIRCULATIONAHA.107.741181
Sosnovik DE, Nahrendorf M, Weissleder R. Molecular magnetic resonance imaging in cardiovascular medicine. Circulation. 2007;115:2076–2086. Available from: doi.org/10.1161/circulationaha.106.658930
Heidt T, Nahrendorf M. Multimodal iron oxide nanoparticles for hybrid biomedical imaging. NMR Biomed. 2012;26:756–765. Available from: doi.org/10.1002/nbm.2872
Lee DE, Koo H, Sun IC, Ryu JH, Kim K, Kwon IC. Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem. Soc. Rev. 2012;41:2656–2672. Available from: doi.org/10.1039/c2cs15261d
Park JH, Von MG, Ruoslahti E, Bhatia SN, Sailor MJ. Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery. Angew. Chem. Int. Ed. Engl. 2008;47:7284–7288. Available from: doi.org/10.1002/anie.200801810
Josephson L, Kircher MF, Mahmood U, Tang Y, Weissleder R. Near-infrared fluorescent nanoparticles as combined mr/optical imaging probes. Bioconjugate Chem. 2002:13:554–560. Available from: doi.org/10.1021/bc015555d
Cha EJ, Jang ES, Sun IC, Lee IJ, Ko JH, Kim YI, et al. Development of mri/nirf ‘activatable’ multimodal imaging probe based on iron oxide nanoparticles. J. Control. Release. 2011;155:152–158. Available from: doi.org/10.1016/j.jconrel.2011.07.019
He X, Gao J, Gambhir SS, Cheng Z. Near-infrared fluorescent nanoprobes for cancer molecular imaging: Status and challenges. Trends Mol. Med. 2010;16:574–583. Available from: doi.org/10.1016/j.molmed.2010.08.006
Lee H, Yu MK, Park S, Moon S, Min JJ, Jeong YY, et al. Thermally cross-linked superparamagnetic iron oxide nanoparticles: Synthesis and application as a dual imaging probe for cancer in vivo. J. Am. Chem. Soc. 2007;129:12739–12745. Available from: doi.org/10.1021/ja072210i
Hasebroock KM, Serkova NJ. Toxicity of mri and ct contrast agents. Expert Opin. Drug Metabol. Toxicol. 2009:5:403–416. Available from: doi.org/10.1517/17425250902873796
Glare P, Jongs W, Zafiropoulos B. Establishing a cancer nutrition rehabilitation program (CNRP) for ambulatory patients attending an Australian cancer center. Support Care Cancer. 2011; 19:445–454. Available from: doi.org/10.1007/s00520-010-0834-9
Chasen MR, Dippenaar AP. Cancer nutrition and rehabilitation – its time has come! Curr Oncol. 2010; 15:1–6. Available from: doi.org/10.3747/co.v15i3.244
Del FE, Hui D, Shalini D, et al. Clinical outcomes and contributors to weight loss in a cancer cachexia clinic. J Palliat Med. 2011;14:1–5. Available from: doi.org/10.1089/jpm.2011.0098
Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic nonsmall cell lung cancer. N Engl J Med. 2010;363:733–742. Available from: doi.org/10.1056/nejmoa1000678
Wheelwright SJ, Johnson CD. Patient-reported outcomes in cancer cachexia clinical trials. Curr Opin Support Palliat Care. 2015;9:325–332. Available from: doi.org/10.1097/spc.0000000000000168
Pene F, Courtine E, Cariou A, Mira JP. Toward theragnostics. Crit. Care Med. 2009;37:S50-S58. Available from: doi.org/10.1097/ccm.0b013e3181921349
Ozdemir V, Williams-Jones B, Glatt SJ, Tsuang MT, Lohr JB, Reist C. Shifting emphasis from pharmacogenomics to theragnostics. Nat. Biotechnol. 2006;24:942-947. Available from: doi.org/10.1038/nbt0806-942
Shubayev VI, Pisanic TR, Jin SH. Magnetic nanoparticles for theragnostics. Adv. Drug Deliv. Rev. 2009;61:467-477. Available from: doi.org/10.1016/j.addr.2009.03.007
Del VS, Zannetti A, Fonti R, Pace L, Salvatore M. Nuclear imaging in cancer theranostics. Q. J. Nucl. Med. Mol. Imaging. 2007;51:152-163.
Lucignani, G. Nanoparticles for concurrent multimodality imaging and therapy: the dawn of new theragnostic synergies. Eur. J. Nucl. Med. Mol. Imaging. 2009;36:869-874. Available from: doi.org/10.1007/s00259-009-1104-2
Santra S, Kaittanis C, Grimm J, Perez JM. Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging. Small. 2009;5:1862–1868. Available from: doi.org/10.1002/smll.200900389
Drake P, Cho HJ, Shih PS, Kao CH, Lee KF, Kuo CH, et al. Gd-doped iron-oxide nanoparticles for tumour therapy via magnetic field hyperthermia. J. Mater. Chem. 2007;17:4914. Available from: doi.org/10.1039/B711962C
Silva AC, Oliveira TR, Mamani JB, Malheiros SM, Malavolta L, Pavon LF, et al. Application of hyperthermia induced by superparamagnetic iron oxide nanoparticles in glioma treatment. Int. J. Nanomed. 2011;6:591–603. Available from: doi.org/10.2147/IJN.S14737
Zhao Q, Wang L, Cheng R, Mao L, Arnold RD, Howerth EW, et al. Magnetic nanoparticle-based hyperthermia for head & neck cancer in mouse models. Theranostics. 2012;2:113–121. Available from: doi.org/10.7150/thno.3854
Laurent S, Dutz S, Hafeli UO, Mahmoudi M. Magnetic fluid hyperthermia: Focus on superparamagnetic iron oxide nanoparticles. Adv. Colloid Interface Sci. 2011;166:8–23. Available from: doi.org/10.1016/j.cis.2011.04.003
Lee JH, Lee K, Moon SH, Lee Y, Park TG, Cheon J. All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and sirna delivery. Angew. Chem. Int. Ed. Engl. 2009;48:4174–4179. Available from: doi.org/10.1002/anie.200805998
Wang YX. Superparamagnetic iron oxide based mri contrast agents: Current status of clinical application. Quant. Imag. Med. Surg. 2011;1:35–40. Available from: doi.org/10.3978/j.issn.2223-4292.2011.08.03
Kim DK, Kim JW, Jeong YY, Jon SY. Antibiofouling polymer coated gold@iron oxide nanoparticle (gion) as a dual contrast agent for ct and mri. Bull. Korean Chem. Soc. 2009;30:1855–1857. Available from: doi.org/10.5012/bkcs.2009.30.8.1855
Cherry SR. Multimodality imaging: Beyond pet/ct and spect/ct. Semin. Nuclear Med. 2009;39:348–353. Available from: doi.org/10.1053/j.semnuclmed.2009.03.001
Fearon KCH. Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer. 2008;44:1124–1128. Available from: doi.org/10.1016/j.ejca.2008.02.033
MacDonald N. Cancer cachexia and targeting chronic inflammation: a unified approach to cancer treatment and palliative/supportive care. J Support Oncol. 2007; 5:157–162.
Morani DO & Rane BR. Review on different Multimodal Approaches for Multifactorial Cancer Disease. Asian Journal of Pharmacy and Technology. 2024;14(3):264-0. Available from: doi.org/10.52711/2231-5713.2024.00043
Published
Abstract Display: 59 
PDF Downloads: 18 How to Cite
Issue
Section
Copyright (c) 2025 Dilip Morani, Mangesh Tote, Pavankumar Chopade, Kashmira Pingulkar, Mayuri Baviskar, Ankita Gaikwad, Manjusha Sanap, Mangesh Bansod
This work is licensed under a Creative Commons Attribution 4.0 International License.
